Cargando…

Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes

The levels of several glial and neuronal plasma biomarkers have been found to increase during the acute phase in COVID-19 patients with neurological symptoms. However, replications in patients with minor or non-neurological symptoms are needed to understand their potential as indicators of CNS injur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lennol, Matthew P., Ashton, Nicholas J., Moreno-Pérez, Oscar, García-Ayllón, María-Salud, Ramos-Rincon, Jose-Manuel, Andrés, Mariano, León-Ramírez, José-Manuel, Boix, Vicente, Gil, Joan, Blennow, Kaj, Merino, Esperanza, Zetterberg, Henrik, Sáez-Valero, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917569/ https://www.ncbi.nlm.nih.gov/pubmed/36769057 http://dx.doi.org/10.3390/ijms24032715

Ejemplares similares

Plasma ACE2 species are differentially altered in COVID‐19 patients
por: García‐Ayllón, María‐Salud, et al.
Publicado: (2021)

Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer’s Disease Patients
por: Lopez-Font, Inmaculada, et al.
Publicado: (2022)

Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy
por: Lennol, Matthew P., et al.
Publicado: (2022)

C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease
por: García-Ayllón, María-Salud, et al.
Publicado: (2017)

Levels of ADAM10 are reduced in Alzheimer’s disease CSF
por: Sogorb-Esteve, Aitana, et al.
Publicado: (2018)

Inhibition of γ-Secretase Leads to an Increase in Presenilin-1
por: Sogorb-Esteve, Aitana, et al.
Publicado: (2017)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lennol, Matthew Paul, et al.
Publicado: (2022)

Neurological Assessment and Its Relationship to CSF Biomarkers in Amateur Boxers
por: Neselius, Sanna, et al.
Publicado: (2014)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

CSF Presenilin-1 complexes are increased in Alzheimer’s disease
por: García-Ayllón, María-Salud, et al.
Publicado: (2013)

Editorial: Blood Biomarkers of Neurodegenerative Diseases
por: Karikari, Thomas K., et al.
Publicado: (2022)

Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study
por: Bromander, Sara, et al.
Publicado: (2012)

Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up
por: Kanberg, Nelly, et al.
Publicado: (2021)

Bacteraemia and quick Sepsis Related Organ Failure Assessment (qSOFA) are independent risk factors for long-term mortality in very elderly patients with suspected infection: retrospective cohort study
por: Hernández-Quiles, Rubén, et al.
Publicado: (2022)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Commentary: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
por: Karikari, Thomas K., et al.
Publicado: (2018)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
por: Yilmaz, Aylin, et al.
Publicado: (2019)

Heteromers of amyloid precursor protein in cerebrospinal fluid
por: Cuchillo-Ibañez, Inmaculada, et al.
Publicado: (2015)

Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study
por: Moreno-Pérez, Oscar, et al.
Publicado: (2020)

Transient increase in CSF GAP-43 concentration after ischemic stroke
por: Sandelius, Åsa, et al.
Publicado: (2018)

N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
por: Snellman, Anniina, et al.
Publicado: (2022)

Post-COVID syndrome. The never ending challenge()
por: Boix, Vicente, et al.
Publicado: (2022)

Síndrome post-COVID. El desafío continúa
por: Boix, Vicente, et al.
Publicado: (2022)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders
por: Eide, Per Kristian, et al.
Publicado: (2023)

Revisiting the Role of Acetylcholinesterase in Alzheimer’s Disease: Cross-Talk with P-tau and β-Amyloid
por: García-Ayllón, María-Salud, et al.
Publicado: (2011)

Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients
por: Moreno-Pérez, Oscar, et al.
Publicado: (2020)

GFAp and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: A post hoc analysis of the COMACARE trial
por: Humaloja, Jaana, et al.
Publicado: (2022)

The quick Sepsis-related Organ Failure Assessment (qSOFA) is a good predictor of in-hospital mortality in very elderly patients with bloodstream infections: A retrospective observational study
por: Ramos-Rincón, José M., et al.
Publicado: (2019)

Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID‐19 and associated with neurological symptoms and disease severity
por: Virhammar, Johan, et al.
Publicado: (2021)

Biomarkers for tau pathology
por: Schöll, Michael, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6o30im990diuruddulhgj0rip0